Who are Abzena's investors?

Abzena's investors include Beringea, BIOSPRING PARTNERS, WCAS, Welsh, Carson, Anderson & Stowe.

How much funding has Abzena raised?

Abzena has disclosed $4.3M raised across 2 of its 3 known rounds.

Where is Abzena headquartered?

Abzena is headquartered in Cambridge, US.

Abzena

Cambridge, US · Founded 2014 · United Kingdom corporation · 438 employees on LinkedIn · 5 known investors

Abzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs. It serves biotech, academic, and pharmaceutical customers across the drug development lifecycle from discovery through commercial manufacturing.

Advanced Manufacturing Biotech Healthtech Medical Devices

Founders & leadership

William John Edward BurtExecutive

Nigel PitchfordNamed on SEC filing

Leigh PierceNamed on SEC filing

Kenneth CunninghamNamed on SEC filing

Julian SmithNamed on SEC filing

Anthony BramptonNamed on SEC filing

Anker LundemoseNamed on SEC filing

Peter GrantNamed on SEC filing

Matthew BakerNamed on SEC filing

Investors · 5

BeringeaLondon · $3M – $10M

BIOSPRING PARTNERSNew York

WCASNew York

Welsh, Carson, Anderson & Stowereported

Also in the syndicate · 1

Welsh, Carson, Anderson & Stowe (WCAS)

Reported raises · per SEC filings

Form D private placements

$4.3M disclosed across 2 of 3 rounds · 2015–2022

▶$3.6MraisedDec 2015 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Jim MillsExecutive Officer
Kenneth CunninghamDirector
Campbell BunceExecutive Officer
Nareshkumar JainExecutive Officer
Gary PierceExecutive Officer
Anker LundemoseDirector
Julian SmithExecutive Officer, Director
William John Edward BurtExecutive Officer, Director
Leigh PierceExecutive Officer
Nigel PitchfordDirector
Sally WatermanExecutive Officer
Matthew BakerExecutive Officer
Peter GrantDirector
Anthony BramptonDirector

Offering amount: $3.6M
Amount sold: $3.6M
First sale: Dec 2015
Incorporated: Corporation, United Kingdom, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$700KraisedSep 2015 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Nigel PitchfordDirector
Leigh PierceExecutive Officer
William John Edward BurtExecutive Officer, Director
Kenneth CunninghamDirector
Julian SmithExecutive Officer, Director
Anthony BramptonDirector
Anker LundemoseDirector
Peter GrantDirector
Matthew BakerExecutive Officer

Offering amount: $700K
Amount sold: $700K
First sale: Sep 2015
Incorporated: Corporation, United Kingdom, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Abzena went on to found or lead other companies.

Michelle DetwilerBoard of DirectorsFounded Biospring Geoffrey GlassInterim CEOFounded Kiniciti

Competitors · 2

by search overlap

Catalent90 shared keywordsCatalent is a global Contract Development and Manufacturing Organization (CDMO) that helps pharma, biotech, and self-care companies develop, manufacture, and deliver drug products and consumer health solutions. Its services span oral dose, biologics, specialty, and clinical supply, from early-stage design through commercial manufacturing.

Pharmaron78 shared keywordsPharmaron is a contract research and manufacturing organization providing drug development and manufacturing services to pharmaceutical and biotech companies.

Companies competing with Abzena for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Abzena Secures $65 Million in Additional Funding to Accelerate Growth and Expand Capacity | Abzenaabzena.com · Mar 2022

Abzena Receives $10M in Growth Funding - FinSMEsfinsmes.com · Jul 2020

Frequently asked questions

What does Abzena do?: Abzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs. It serves biotech, academic, and pharmaceutical customers across the drug development lifecycle from discovery through commercial manufacturing.
Who are Abzena's investors?: Abzena's investors include Beringea, BIOSPRING PARTNERS, WCAS, Welsh, Carson, Anderson & Stowe.
How much funding has Abzena raised?: Abzena has disclosed $4.3M raised across 2 of its 3 known rounds.
Where is Abzena headquartered?: Abzena is headquartered in Cambridge, US.